Horizon Discovery hosts Capital Markets Day today
March 05 2018 - 7:00AM
Horizon Discovery Group plc
Horizon Discovery hosts Capital Markets Day
today
Cambridge, UK, 5 March 2018: Horizon
Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global
leader in gene editing and gene modulation technologies, will today
hold a Capital Markets Day in London for institutional investors
and analysts between 13:00 - 15:00 GMT / 08:00 - 10:00 EDT at Etc.
Venues Fenchurch Street, 43/44 Crutched Friars, London, EC3N
2HH. Registration for those attending in person will begin at 12:30
to ensure a prompt 13:00 start. A light lunch will be provided. No
new price sensitive information will be disclosed.
The agenda for the session, commencing at 13:00
GMT / 08:00 EDT today, will include:
- Richard Vellacott, Interim Chief Executive Officer:
Horizon Strategy and Vision
- Richard Vellacott: FY17 Trading
- Terry Pizzie, Head of Commercial: Commercial Delivery
- Chris Lowe, Head of Research Operations: Delivery of our
Research Operations
- Kim Nichols, Head of Global Operations: Dharmacon Business and
Integration
- Jon Moore, Head of Translational R&D: Leveraged
Research
- Tom Henley, Head of Innovation: Driving our Core
Innovation
- Richard Vellacott: Summary and Q&A
The event will simultaneously be available via a
live conference call and webcast at
https://www.horizondiscovery.com/about-us/investor-relations.
A recording will be made available shortly after the event.
To dial in to the conference call, please follow
these numbers:
Dialling in from the UK: +44 (0)330 336
9411Dialling in from the US: +1 929-477-0353Confirmation code:
7131835
Please contact horizon@consilium-comms.com if
you would like to attend today's event and have not already
registered.
ENDS
For further information from Horizon Discovery Group plc,
please contact:
Horizon Discovery Group plcRichard
Vellacott, Interim Chief Executive OfficerTel: +44 (0) 1223 655
580
Numis Securities Limited (Broker and
NOMAD)Michael Meade / Freddie Barnfield Tel: +44 (0) 207 260
1000
Consilium Strategic Communications (Financial
Media and Investor Relations)Mary-Jane Elliott / Matthew Neal /
Melissa GardinerTel: +44 (0) 20 3709 5701Email:
horizon@consilium-comms.com
About Horizon Discovery Group plc
www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD)
("Horizon") is a world leader in gene editing and gene modulation
technologies. Horizon designs and engineers cells using its
translational genomics platform, a highly precise and flexible
suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and,
following the acquisition of Dharmacon, Inc., its functional
genomics platform comprising gene knockdown (RNAi) and gene
expression (cDNA, ORF) tools, for research and clinical
applications that advance human health. Horizon's platforms and
capabilities enable researchers to alter almost any gene or
modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue
products and related research services to support a greater
understanding of the function of genes across all species and
the genetic drivers of human disease and the
development of personalised molecular, cell and gene therapies.
These have been adopted by over 10,000 academic, drug
discovery, drug manufacturing and clinical diagnostics customers
around the globe, as well as in the Company's own R&D
pipeline.
Horizon is headquartered in Cambridge, UK, and
is listed on the London Stock Exchange's AIM market under the
ticker "HZD".
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2023 to Apr 2024